ZAGENO, a Cambridge, Massachusetts, startup selling procurement software to life-sciences companies, has opened an office at Two Embarcadero Center in San Francisco. The move gives the company a local base from which to sell a proposition that is less about laboratory science than the systems surrounding it: purchasing supplies can consume researchers’ time, create administrative work and leave projects exposed to delays. The San Francisco Examiner reported that ZAGENO is using the office to test whether Bay Area biotechs will pay to simplify that process.
The problem ZAGENO is selling
ZAGENO says scientists spend about 6.5 hours a week sourcing and ordering materials. It also claims that decentralized purchasing can make supplies 15% to 20% more expensive and that stockouts can delay milestones by two to four weeks, according to the Examiner’s account. Those figures are the company’s sales case, not independently verified measurements presented in the available reporting.
The platform combines a supplier marketplace with purchasing-workflow tools. ZAGENO says researchers can search more than 50 million products from over 6,000 suppliers, place orders from multiple vendors in one cart and consolidate invoices for payment. The company also says its system connects with enterprise procurement and finance tools; its official biotech page lists integrations including SAP Ariba, Coupa, Jaggaer and Oracle Business Network. ZAGENO’s procurement page describes those capabilities, while the Examiner identified NetSuite, SAP and Coupa among systems discussed in connection with the product.
A market with competitors
ZAGENO is not the only company presenting procurement as a specialized biotech-operations problem. MyAmici, a separate biotech procurement platform, says its software provides access to thousands of suppliers and millions of products through a lab-operations platform. MyAmici’s official site does not establish how its performance compares with ZAGENO’s, but it shows that supplier discovery and purchasing workflows are already being marketed as a distinct software category for research organizations.
That competitive setting makes ZAGENO’s San Francisco location strategically useful but not conclusive. The office may support sales and customer relationships in a major biotech region; its existence does not show that local laboratories have adopted the platform or that the company’s claimed savings will translate across different organizations, purchasing rules and enterprise systems.
What the company says customers achieved
ZAGENO points to customer case studies rather than independent evaluations. In one account, the company says Apogee Therapeutics consolidated 98 suppliers, reduced purchase-order volume by 40% and returned more than 250 hours to scientists; ZAGENO’s case study values that time at more than $260,000. Another company case study describes purchasing automation rising from 6% to 91% and says the customer avoided $132,000 in annualized costs. That account does not, on the available page, independently verify the figures or identify enough operating detail to determine whether the result is typical.
Why timing matters
The expansion comes during a difficult period for Bay Area life sciences. The Examiner reported regional vacancy of 30.7% at the end of the first quarter of 2026, while South San Francisco added 630,000 square feet of sublease space. Recent disclosures cited in the reporting include 121 planned job cuts at bioMérieux’s San Jose office, a major workforce reduction at Theravance Biopharma and 103 layoffs tied to a Genentech restructuring. Fierce Biotech and Silicon Valley news reporting document additional cuts, but those events do not by themselves demonstrate that procurement software demand is rising.
Founded in 2015 by Florian Wegener and David Pumberger, ZAGENO has raised roughly $121 million, including a $20 million Series B led by General Catalyst in 2019 and $33 million in 2023, according to the Examiner. The San Francisco office now gives the company a chance to turn a broadly stated efficiency problem into recurring local contracts. Whether cost-conscious laboratories view centralized purchasing as essential infrastructure—or simply another software expense—remains unresolved.
